Atara Bio Concludes EMA Scientific Advice and Plans to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
49
Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that pursuant to parallel scientific advice from the European Medicines Agency’s (EMA’s) Scientific Advice Working Group and several national Health Technology Assessment (HTA) Agencies in the EU, the Company plans to submit in 2018 an application for Conditional Marketing Authorization Approval (Conditional MAA) of ATA 129 in the treatment of patients with rituximab refractory EBV-PTLD following hematopoietic cell transplant (HCT). The Conditional MAA will be based on clinical data from Phase 1 and 2 trials conducted at Memorial Sloan Kettering Cancer Center (MSK) and supported by available data from the Company’s Phase 3 studies in rituximab refractory EBV-PTLD after HCT and solid organ transplantation (SOT), which will be ongoing at the time of filing.

Participating in the Scientific Advice meeting were HTAs representing England and Wales, (National Institute for Clinical Excellence [NICE]), Germany (Gemeinsamen Bundesausschuss [G-BA]), and France (Haute Autorité de Santé [HAS]).  A separate meeting was also held with G-BA.  Based on the feedback received in these discussions, the Company is moving forward to compile information in support of potential product reimbursement.

"We are very pleased with the outcome of our discussions with the EMA’s Scientific Advice Working Group and the HTAs," noted Isaac Ciechanover, M.D., President, and Chief Executive Officer of Atara Bio. "We look forward to submitting our Conditional MAA in 2018."

The European Medicines Agency (EMA) supports the development of medicines that address unmet medical needs of patients. In the interest of public health, medicines may be eligible for conditional marketing authorization if they are aimed at treating, preventing or diagnosing seriously debilitating or life-threatening diseases, intended for use in emergency situations, or designated as orphan medicines. Applicants may be granted a conditional marketing authorization if the CHMP finds that the benefit-risk balance of the product is positive; it is likely that the applicant will be able to provide comprehensive data at a later date; unmet medical needs will be fulfilled; and the benefit to public health of the medicinal product's immediate availability on the market outweighs the risks due to the request for further data.

In October 2016, ATA 129 was granted access to the EMA’s newly established Priority Medicines (PRIME) regulatory initiative for the treatment of patients with rituximab refractory EBV-PTLD following HCT. Access to the Priority Medicines initiative is granted by the EMA to support the development and accelerate the review of new therapies to treat patients with unmet medical need.

The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to ATA 129 for the treatment of patients with rituximab refractory EBV-PTLD after HCT in February 2015.

About EBV-CTL

EBV is associated with a wide range of hematologic malignancies and solid tumors, as well as certain autoimmune conditions such as multiple sclerosis.  In patients with weakened immune systems, including those who have received an HCT or SOT, EBV infection can result in an aggressive B-cell lymphoma called EBV-PTLD. T-cells are a critical component of the body's immune system and can be harnessed to counteract viral infections and some cancers. By focusing the T-cells on specific proteins involved in the cancers and infections, the power of the immune system can be employed to combat these diseases. Atara's EBV-CTL utilizes a technology in which T-cells are collected from the blood of third-party donors and then exposed to EBV antigens. The resulting activated T-cells are then expanded, characterized, and stored for future therapeutic use in an appropriate partially human leukocyte antigen, or HLA, matched patient, providing an allogeneic, cellular therapeutic option for patients.  In the context of EBV infection, Atara's EBV-CTL finds the cells expressing EBV and kills them. EBV-CTL is currently being studied in ongoing Phase 2 clinical trials in patients with EBV-associated cancers, including PTLD and nasopharyngeal carcinoma. EBV-CTL is also available to eligible patients with PTLD through an ongoing multicenter expanded access protocol trial.

About Atara Biotherapeutics’ Allogeneic Cellular Therapy Platform

Atara Bio’s cellular therapy platform provides healthy immune capability to a patient and arms the immune system to precisely target and combat disease. Cells derived from healthy donors are manufactured in advance and stored as inventory so that a customized unit of cells can be chosen for each patient. The cells are ready to infuse in approximately 3 to 5 days. Once administered, the cells home to their target, expand in-vivo to eliminate diseased cells, and eventually recede. This versatile platform can be directed towards a broad array of disease causing targets and has demonstrated clinical proof of concept across both viral and non-viral targets in conditions ranging from liquid and solid tumors to infectious and autoimmune diseases. The company has pursued prospective feedback from health authorities on both manufacturing and clinical trial design. Its lead product candidate has the potential to be the first commercial allogeneic T-cell therapy for a viral target implicated in cancer.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, or ATA 129, Cytomegalovirus targeted Cytotoxic T-cells (CMV-CTL), or ATA 230, and Wilms Tumor 1 targeted Cytotoxic T-cells (WT1-CTL), or ATA 520, and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding the Company’s plans to submit a Conditional MAA for ATA 129 in the treatment of patients with rituximab refractory EBV-PTLD following hematopoietic cell transplant (HCT) based on clinical data from Phase 1 and 2 trials conducted at Memorial Sloan Kettering Cancer Center (MSK) and supported by available data from the Company’s Phase 3 studies in rituximab refractory EBV-PTLD after HCT and solid organ transplantation (SOT), which will be ongoing at the time of filing; and the Company’s plan to file the Conditional MAA in 2018. Because such statements deal with future events and are based on Atara Bio's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Bio could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those discussed under the heading "Risk Factors" in Atara Bio's annual report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2016, including the documents incorporated by reference therein, and subsequent filings with the SEC. Except as otherwise required by law, Atara Bio disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR & MEDIA CONTACTS: Investors: Steve Klass, Burns McClellan on behalf of Atara Bio 212-213-0006 x331 sklass@burnsmc.com Media: Justin Jackson, Burns McClellan 212-213-0006 x327 jjackson@burnsmc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 99

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 27

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 235

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 254

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 148

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 489

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

YouTube Shuts Down Tenet Media Channel Amid Legal Issues

Updated Category News Views 305

YouTube's Action Against Tenet Media Explained YouTube, which is part of Alphabet (NASDAQ: GOOGL), has made a significant move by shutting down the Tenet Media channel, along with four other channels managed by Lauren Chen. This decision comes in response to serious legal actions taken by the U.S. Department of Justice against certain individuals involved in money...

Continue Reading
Ardelyx Faces Class Action Lawsuit Amidst Investment Losses

Updated Category News Views 112

Important Update for Ardelyx Investors Regarding Class Action Pomerantz LLP has recently informed shareholders about a class action lawsuit involving Ardelyx, Inc. This lawsuit targets both the company and its key officers, alleging violations of federal securities laws. Investors who held Ardelyx securities during a specified timeframe should pay close attention to this...

Continue Reading
Derek Bryson Park: Innovator Transforming Finance Worldwide

Updated Category News Views 205

Celebrating Derek Bryson Park's Impact on Finance Derek Bryson Park has recently been highlighted by The Enterprise World Magazine as a key figure in the financial industry, a well-deserved recognition for his extensive and impactful career. With three decades of experience, Park continues to innovate in finance, public service, and global diplomacy. Pioneering Leadership...

Continue Reading
Understanding Currency Impacts in Global Trade Dynamics

Updated Category News Views 291

Understanding Currency Impacts in Global Trade Dynamics Scott Bessent, a noted figure in finance, is igniting conversations regarding tariffs and trade in recent discussions. All eyes on Wall Street are focused on how these changes influence market dynamics. Initially, any reduction in the U.S. trade deficit with other nations may seem like a significant win for the...

Continue Reading
Pennant Group Expands Its Operations with Recent Acquisition

Updated Category News Views 283

Pennant Group's Strategic Acquisition Announcement The Pennant Group, Inc. (NASDAQ: PNTG), a prominent holding company in the healthcare industry, recently achieved a significant milestone by acquiring specific operational assets from UnitedHealth Group Incorporated. This notable transaction was made possible due to UnitedHealth’s acquisition of Amedisys Inc., enabling...

Continue Reading